ARS Sets Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)

  ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced that the United States (U.S.) Food and Drug Administration (FDA) has scheduled a Type A meeting to discuss the contents of a Complete Response Letter (CRL) previously issued regarding its new drug application (NDA) for neffy® (epinephrine nasal spray) for the treatment of allergic reactions (Type I), including anaphylaxis.

The Type A meeting with FDA will be held by the end of October.

https://www.biospace.com/article/releases/ars-pharmaceuticals-announces-scheduling-of-a-type-a-meeting-with-the-u-s-fda-for-neffy-epinephrine-nasal-spray-/